Dr. Mark W Pomerantz - NPI #1184700551

Cardiovascular Disease Doctor located in West Nyack, NY

New York West Nyack Cardiovascular Disease Dr. Mark W Pomerantz Information


Dr. Mark W Pomerantz is a male Cardiovascular Disease Doctor (taxonomy code 207RC0000X) located in West Nyack, New York. Dr. Mark W Pomerantz primarily specializes in Cardiovascular Disease but also specializes in Interventional Cardiology and Nuclear Cardiology. Dr. Mark W Pomerantz's NPI Number is #1184700551 and has been listed in the NPI registry for 12 years. Dr. Mark W Pomerantz's practice location is listed as: 2 Crosfield Ave Suite 407 West Nyack, NY 10994 and can be reached via phone at (845) 353-5050.

Cardiovascular Disease Taxonomy

The taxonomy code for Dr. Mark W Pomerantz's main specialty, Cardiovascular Disease, is 207RC0000X. An internist who specializes in diseases of the heart and blood vessels and manages complex cardiac conditions such as heart attacks and life-threatening, abnormal heartbeat rhythms.



Be the first to rate Dr. Pomerantz

Thanks for sharing your opinion!

‡ Descriptions, provider messages, and reviews are user submitted. While we make our best effort to verify the accuracy of information submissions, DocBios cannot guarantee that the information is accurate and/or up to date. Please verify any and/or all information with the provider. DocBios is not an advice or referral service and does not guarantee, approve, or endorse any particular healthcare provider.

Health Care Provider Information
 NPI # 1184700551
 Phone (845) 353-5050
 Fax (845) 353-1285
2 Crosfield Ave
Suite 407
West Nyack, NY 10994
 Gender M
 Website Not provided
  • Cardiovascular Disease (NJ)
  • Interventional Cardiology (NY)
  • Nuclear Cardiology (NJ)
Business Information
  • Sole Proprietor? No
  • Is Sub-Organization? Not Available
  • Parent Org Name: Not Available
 Updated 1/8/2015
 Added 10/28/2006
 Viewed on 4/22/2018
Health Care Providers Nearby

Thanks! Your edit was sucessfully submitted. Changes will be displayed after DocBios.com editors have reviewed your submission.